TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties (Q39486061)

12 September 2017

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties (English)

1 reference

12 September 2017

1 reference

K C Goh

1

1 reference

12 September 2017

V Novotny-Diermayr

2

1 reference

12 September 2017

S Hart

3

1 reference

12 September 2017

L C Ong

4

1 reference

12 September 2017

Y K Loh

5

1 reference

12 September 2017

A Cheong

6

1 reference

12 September 2017

Y C Tan

7

1 reference

12 September 2017

C Hu

8

1 reference

12 September 2017

R Jayaraman

9

1 reference

12 September 2017

A D William

10

1 reference

12 September 2017

E T Sun

11

1 reference

12 September 2017

B W Dymock

12

1 reference

12 September 2017

K H Ong

13

1 reference

12 September 2017

K Ethirajulu

14

1 reference

12 September 2017

F Burrows

15

1 reference

12 September 2017

J M Wood

16

1 reference

12 September 2017

23 August 2011

1 reference

12 September 2017

1 reference

12 September 2017

26

1 reference

12 September 2017

236-243

1 reference

12 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.218

12 September 2017

0 references

cites work

Targeted inhibition of kinases in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Novel inhibitors in development for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Pharmacological inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

The JAK/STAT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Recent advances in the bcr-abl negative chronic myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

The exploration of macrocycles for drug discovery--an underexploited structural class

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Kinases as drug discovery targets in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.218

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.218

1 reference

12 September 2017

1 reference